FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval

Dispute resolution win means focus for antidepressant Travivo (gepirone extended-release) shifts to labeling, post-marketing and manufacturing despite going 2 for 12 in clinical trials.